胆汁淤积性肝病相关并发症的处理*

doi:10.3969/j.issn.1672-5069.2019.06.041

Abstract

Ding Wenjin, Fan Jiangao.. Management of complications associated with cholestatic liver disease[J]. Journal of Practical Hepatology, 2019, 22(6): 938-940.

[1] AI-Dury S,Wahlstr<inline-graphic xlink:href="-22-6-938/img_1.png"/>m A,Wahlin S,et al. Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis. Sci Rep,2018,8:6658.
[2] Beuers U,Kremer AE,Bolier R,et al.Pruritus in cholestasis:facts and fiction. Hepatology,2014,60(1):399-407.
[3] Onofrio FQ,Hirschfield GM,Gulamhusein AF.A practical review of primary biliary cholangitis for the gastroenterologist. Gastroenterol Hepatol,2019,15(3):145-154.
[4] 中华医学会肝病学分会,中华医学会消化病学分会,中华医学会感染病学分会. 胆汁淤积性肝病诊断和治疗共识(2015年). 实用肝脏病杂志. 2016,19(6):771-781.
[5] Jin XY,Khan TM.Quality of life among patients suffering from cholestatic liver disease-inducedpruritus:A systematic review. J Formos Med Assoc,2016,115(9):689-702.
[6] Ataei S,Kord L,Larki A,et al.Comparison of sertraline with rifampin in the treatment of cholestatic pruritus:A randomized clinical trial. Rev Recent Clin Trials,2019,[Epub ahead of print].
[7] De Vloo C,Nevens F.Cholestatic pruritus:an update. Acta Gastroenterol Belg,2019,82(1):75-82.
[8] Hegade VS,Krawczyk M,Kremer AE,et al.The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus:a multicentre European study. Aliment Pharmacol Ther,2016,43(2):294-302.
[9] Poupon RE,Chrétien Y,Chazouillères O,et al.Quality of life in patients with primary biliary cirrhosis. Hepatology,2014,40:489-494.
[10] Jopson L,Jones DEJ.Fatigue in primary biliary cirrhosis:prevalence,pathogenesis and management. Dig Dis,2015,33:109-114.
[11] 陆伦根. 胆汁淤积性肝病肝外并发症诊治研究进展. 中华肝脏病杂志,2016,24(8):561-564.
[12] Silveira MG,Gossard AA,Stahler AC,et al.A randomized,placebo-controlled clinical trial of efficacy and safety:Modafinil in the treatment of fatigue in patients with primary biliary cirrhosis. Am J Ther,2017,24(2):e167-e176.
[13] Khanna A,Jopson L,Howel D,et al.Rituximab is ineffective for treatment of fatigue in primary biliary cholangitis:A phase 2 randomized controlled trial. Hepatology,2018,[Epub ahead of print].
[14] Lee JY,Danford CJ,Trivedi HD,et al.Treatment of fatigue in primary biliary cholangitis:A systematic review and Meta-analysis. Dig Dis Sci,2019,[Epub ahead of print].
[15] Gossard AA,Lindor KD.Current and promising therapy for primary biliary cholangitis. Expert Opin Pharmacother,2019,20(9):1161-1167.
[16] Guanabens N,Parés A.Osteoporosis in chronic liver disease. Liver Int,2018,38(5):776-785.
[17] Guanabens N,Ruiz-Gaspa S,Gifre L,et al.Sclerostin expression in bile ducts of patients with chronic cholestasis may influence the bone disease in primary biliary cirrhosis. J Bone Miner Res,2016,31:1725-1733.
[18] Schmidt T,Schwinge D,Rolvien T,et al.Th17 cell frequency is associated with low bone mass in primary sclerosing cholangitis. J Hepatol,2019,70(5):941-953.
[19] Danford CJ,Trivedi HD,Papamichael K,et al.Osteoporosis in primary biliary cholangitis. World J Gastroenterol,2018,24(31):3513-3520.
[20] Khosla S,Hofbauer LC.Osteoporosis treatment:recent developments and ongoing challenges. Lancet Diabetes Endocrinol,2017,5:898-907.
[21] Danford CJ,Ezaz G,Trivedi HD,et al.The pharmacologic management of osteoporosis in primary biliary cholangitis:A systematic review and Meta-analysis.J Clin Densitom,2019,[Epub ahead of print].
[22] 陆伦根. 胆汁淤积性肝病的正确认识与科学管理. 实用肝脏病杂志,2019,22(5):754-757.

Management of complications associated with cholestatic liver disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. [J]. Journal of Practical Hepatology, 2019, 22(5): 624-635.
[2]	Lu Lungen. Cholestatic liver diseases：What we know and how to deal with [J]. Journal of Practical Hepatology, 2019, 22(5): 754-757.
[3]	Hong Jia, Wu Xiaoning, You Hong. Standardized diagnosis of cholestatic liver diseases [J]. Journal of Practical Hepatology, 2019, 22(5): 758-760.
[4]	Tang Chengwei. Chronic liver disease and thrombocytopenia：Changes in clinical management concept [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 457-458.
[5]	Lu Ximei, Kang Yanfei, Song Zhiyong, et al. Application of color Doppler ultrasonography in the diagnosis of biliary complications in patients after liver transplantation [J]. Journal of Practical Hepatology, 2019, 22(4): 589-592.
[6]	Ma Xinkui, Liu Yong, Zhang Wei. Two-year follow up of patients with intrahepatic cholelithiasis after percutaneous transhepatic choledochoscopic lithotripsy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 593-596.
[7]	Su Shuting, Zhong Yan, Mi Yuqiang.. Management of patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 293-296.
[8]	Ding Yang, Dou Xiaoguang.. How to achieve zero mother-to-child transmission of hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 4-5.
[9]	Zhu Yage, Lei Chunmei, Guo Dandan, et al.. Followed-up and management of pregnant women with chronic hepatitis B viral infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 45-48.
[10]	Yang Ruixu, Fan Jiangao. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 496-501.
[11]	Yu Aidong, Wang Chuanjie, Li Jianfang. Application of group management by WeChat in improving compliance of patients with chronic hepatitis B receiving nucleos(t)des [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 621-622.
[12]	Guo Wei, Zhao Jinyu, Qi Chunyan. Pain management on the quality of life in patients with advanced primary liver cancer [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 641-642.
[13]	Zhang Ming, Zhuge Yuzheng, Zou Xiaoping. Application of interventional techniques in patients with unknown etiologic portal hypertension [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 329-331.
[14]	Yang Kaiqi, Chen Shiyao. Prognosis of patients with idiopathic portal hypertension [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 332-335.
[15]	Yu Yang, Chen Zhonghao, Liao Zuofu, et al. Clinical efficacy and related risk factors of complications in alcoholicliver cirrhosis patients with gallstone after laparoscopic cholecystectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 364-367.